In This Article:
Over the last 7 days, the Indian market has remained flat, but it has impressively risen by 41% over the past 12 months. In light of this growth and with earnings expected to increase by 17% per annum in the coming years, identifying promising stocks that are currently underappreciated can be a strategic move for investors.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Wealth First Portfolio Managers | NA | -47.95% | 40.47% | ★★★★★★ |
| Bharat Rasayan | 8.15% | 0.10% | -7.93% | ★★★★★★ |
| Knowledge Marine & Engineering Works | 35.48% | 42.61% | 42.95% | ★★★★★★ |
| Force Motors | 23.24% | 21.52% | 44.24% | ★★★★★☆ |
| Gallantt Ispat | 18.85% | 37.56% | 37.26% | ★★★★★☆ |
| Master Trust | 37.05% | 27.64% | 41.99% | ★★★★★☆ |
| Ingersoll-Rand (India) | 1.05% | 14.88% | 27.54% | ★★★★★☆ |
| Genesys International | 12.13% | 15.75% | 36.33% | ★★★★★☆ |
| KP Green Engineering | 13.73% | 47.60% | 61.28% | ★★★★★☆ |
| Monarch Networth Capital | 32.66% | 31.02% | 50.24% | ★★★★☆☆ |
Let's explore several standout options from the results in the screener.
D. P. Abhushan
Simply Wall St Value Rating: ★★★★☆☆
Overview: D. P. Abhushan Limited engages in the manufacturing, sale, and trading of gold, diamond, platinum, silver, and other precious metals and ornaments in India with a market cap of ₹36.81 billion.
Operations: D. P. Abhushan generates revenue primarily from its Gems & Jewellery segment, amounting to ₹23.74 billion. The company's market cap stands at ₹36.81 billion.
D. P. Abhushan, a smaller player in the Indian jewelry retail sector, reported Q1 2024 sales of ₹5.05 billion and net income of ₹250.77 million, showing significant growth from last year’s figures. The company’s earnings grew by 48.5% over the past year, outpacing its industry’s 23% growth rate, and EBIT covers interest payments 9.3 times over. Debt to equity ratio has improved from 187% to 73%, though net debt to equity remains high at 61%.
-
Get an in-depth perspective on D. P. Abhushan's performance by reading our health report here.
-
Explore historical data to track D. P. Abhushan's performance over time in our Past section.
Marksans Pharma
Simply Wall St Value Rating: ★★★★★★
Overview: Marksans Pharma Limited, along with its subsidiaries, is involved in the research, manufacturing, marketing, and sale of pharmaceutical formulations across the United States, North America, Europe, the United Kingdom, Australia, New Zealand and other international markets with a market cap of ₹119.45 billion.
Operations: Marksans Pharma derives its revenue primarily from the sale of pharmaceutical formulations, amounting to ₹22.68 billion. The company's market cap stands at ₹119.45 billion.